Regulated Cannabis Access in Basel

NCT ID: NCT05522205

Last Updated: 2024-10-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

374 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-31

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The randomised controlled study on regulated cannabis access in pharmacies in Basel aims to investigate the effects of regulated cannabis access on consumption behaviour and mental and physical health in comparison to the illegal market.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project consist of two parts: The first part is a randomised controlled study, the second part is an observational study. The randomised controlled study will last six months. Participants will randomly be assigned to one of two groups: Group 1 has immediately access to regulated cannabis in pharmacies; Group 2 has to wait for six months. After six months all participants will have access to regulated cannabis in pharmacies (oberservational study). Every six month participants will be invited to answer online-questionnaires on their cannabis consumption behavior, their mental and physical health. The entire study lasts 2.5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Use Disorder Mental Health Disorder Physical Illness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

One group has immediately access to regulated cannabis access in pharmacies and the other group has to wait six months until they have regulated cannabis access.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

Immediately regulated cannabis access in pharmacies.

Group Type EXPERIMENTAL

Regulated cannabis access in pharmacies

Intervention Type OTHER

The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.

Control group

During the first six months participants of the control group have to continue to buy their cannabis on the illicit market. Afterthese six months they also have access to regulated cannabis access.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Regulated cannabis access in pharmacies

The study does not investigate the health effects of cannabis. The study investigates the effects of regulated cannabis access on cannabis consumption and health in comparison to the unregulated illegal market.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years, residence in Basel-Stadt, consuming cannabis at least monthly during the last 6 months (positive urine sample)

Exclusion Criteria

* pregnant or breastfeeding, currently suicidal, currently psychotic, current inpatient psychiatric treatment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Basel

OTHER

Sponsor Role collaborator

University Psychiatric Clinics Basel

NETWORK

Sponsor Role collaborator

Psychiatric Services Aargau AG

OTHER

Sponsor Role collaborator

Health Department of the Canton of Basel-Stadt

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marc Walter

Prof. Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Canton Basel-Stadt

Basel, Canton of Basel-City, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

References

Explore related publications, articles, or registry entries linked to this study.

Baltes-Flueckiger L, Steinauer R, Meyer M, Vogel M, Walter M. Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial. Front Psychiatry. 2023 Mar 23;14:1139325. doi: 10.3389/fpsyt.2023.1139325. eCollection 2023.

Reference Type DERIVED
PMID: 37032954 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-01670

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cannabinoids and Biological Reactivity to Stress
NCT06430580 RECRUITING EARLY_PHASE1
Age-Related Effects of THC
NCT04294966 COMPLETED EARLY_PHASE1
Behavioral Pharmacology of THC and Beta-Myrcene
NCT05432284 NOT_YET_RECRUITING PHASE1
Baclofen Effects on Marijuana Dependence
NCT02011516 COMPLETED PHASE2
Opioid and Cannabinoid Interactions
NCT03705559 COMPLETED PHASE1